Quotient Sciences

Drug Discovery · Biotechnology
Data updated Nov 22, 2026Full reportReport a mistake

Facts

as of Nov 22, 2026

Quotient Sciences is a drug development & manufacturing accelerator. As a pharmaceutical CRDMO we support customers from candidate selection to commercial launch. Pharmaceutical CRDMO, Small Molecule Drug Development, Phase 1 Clinical Trials, Drug Manufacturing, Clinical Research.

Employees
201-500estimated range
Official records
Wikidata Q140046011
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Products

Products →

Quotient Sciences has 55 clinical trials on record, 5 under way.

Clinical trials
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
phase 1 · under way · 60 participants · as a collaborator · Healthy Participants
Nov 2026
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
phase 1 · under way · 60 participants · as a collaborator · Friedreich Ataxia; Cardiomyopathies; Central Nervous System Diseases; Neuromusc…
Oct 2026
A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolut…
phase 1 · under way · 16 participants · as a collaborator · Healthy Participants
Oct 2026
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

Quotient Sciences: 80 research papers in five years.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices